HARMONY BIOSCIENCES HOLDINGS
NASDAQ: HRMY (Harmony Biosciences Holdings, I)
Kemas kini terakhir: 1 jam lalu38.76
0.17 (0.44%)
| Penutupan Terdahulu | 38.59 |
| Jumlah Dagangan | 871,473 |
| Harga / Pendapatan (P/E Ke hadapan) | 9.63 |
| Harga / Jualan (P/S) | 2.37 |
| Harga / Buku (P/B) | 2.25 |
| Julat 52 Minggu |
| Margin Keuntungan | 20.50% |
| Margin Operasi (TTM) | 30.45% |
| EPS Cair (TTM) | 2.62 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 19.50% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 18.90% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 24.63% |
| Nisbah Semasa (MRQ) | 3.67 |
| Aliran Tunai Operasi (OCF TTM) | 222.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 143.41 M |
| Pulangan Atas Aset (ROA TTM) | 12.81% |
| Pulangan Atas Ekuiti (ROE TTM) | 24.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Harmony Biosciences Holdings, I | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | 5.0 |
| Kesihatan Kewangan | 4.5 |
| Persekitaran Makro | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Purata | 0.42 |
|
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 11.10% |
| % Dimiliki oleh Institusi | 92.80% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Lsv Asset Management | 30 Jun 2026 | 2,061,242 |
| Armistice Capital, Llc | 30 Jun 2026 | 1,564,000 |
| Two Sigma Investments, Lp | 30 Jun 2026 | 959,136 |
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |